Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glycopyrronium bromide + beclometasone dipropionate + formoterol fumarate
- Development stage
- Unknown
- Lead developer
- Chiesi
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
This drug is a free combination therapy consisting of glycopyrronium bromide (CHF 5259), a long-acting muscarinic M3 receptor antagonist (LAMA), and the fixed combination inhaler Foster (beclometasone dipropionate plus formoterol fumarate). Glycopyrronium acts by blocking muscarinic M3 receptors in bronchial smooth muscle to reduce bronchoconstriction and mucus secretion. Beclometasone is an inhaled corticosteroid that reduces airway inflammation, while formoterol is a long-acting beta2-adrenergic agonist (LABA) that induces bronchodilation. The combination aims to provide enhanced bronchodilation and anti-inflammatory effects for patients with chronic obstructive pulmonary disease (COPD) or asthma. The therapy is delivered via pressurized metered dose inhaler (pMDI)[2][3][4][5].
- Other names
- glycopyrrolate + beclomethasone dipropionate + formoterol fumarateGlyco + Foster
02
Targets
CHRM2 (M2)GR (Glucocorticoid receptor)CHRM3 (M3)ADRB2 (β2)
Beyond the preview
Go deeper on glycopyrronium bromide + beclometasone dipropionate + formoterol fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glycopyrronium bromide + beclometasone dipropionate + formoterol fumarate.